Mattson Financial Services LLC Has $1.01 Million Stock Holdings in Amgen Inc. $AMGN

Mattson Financial Services LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 16.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 3,247 shares of the medical research company’s stock after buying an additional 463 shares during the quarter. Mattson Financial Services LLC’s holdings in Amgen were worth $1,012,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. WBI Investments LLC acquired a new stake in shares of Amgen in the first quarter valued at approximately $1,007,000. Westbourne Investments Inc. lifted its position in shares of Amgen by 5.5% in the first quarter. Westbourne Investments Inc. now owns 1,925 shares of the medical research company’s stock valued at $600,000 after buying an additional 100 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Amgen by 174.3% in the first quarter. Acadian Asset Management LLC now owns 20,328 shares of the medical research company’s stock valued at $6,329,000 after buying an additional 12,918 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Amgen by 9.0% in the first quarter. Geneos Wealth Management Inc. now owns 8,065 shares of the medical research company’s stock valued at $2,513,000 after buying an additional 669 shares during the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Amgen by 17.9% in the first quarter. Focus Partners Wealth now owns 221,488 shares of the medical research company’s stock valued at $69,006,000 after buying an additional 33,626 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.76% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $278.51 on Thursday. The firm has a market cap of $149.94 billion, a P/E ratio of 22.77, a price-to-earnings-growth ratio of 2.43 and a beta of 0.49. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $339.17. The business’s 50 day moving average is $293.29 and its 200-day moving average is $292.22.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the company earned $4.97 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date is Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is 77.84%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Guggenheim initiated coverage on Amgen in a research report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, June 24th. Piper Sandler increased their target price on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. Finally, Raymond James Financial started coverage on Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $304.43.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.